March 31st 2023
In honor of Traumatic Brain Injury Month, held on March 2023, get caught up on some of the latest news in traumatic brain injury as the NeurologyLive® team shares some of our data updates.
Treatment Advancements to Overcome Barriers in the Management of Schizophrenia: Key Considerations for Pharmacists
1.5 Credit / Neurology, Psychiatry
View More
Novel Treatment Approaches for Alzheimer Disease: Considerations for Pharmacists Across Care Settings
1.5 Credits / Neurology
View More
Seizure Clusters: A Review of New Drug Delivery Methods and Emerging Therapy Options
0.50 Credit / Neurology
View More
Novel Non-stimulant ADHD Treatments: A Review for Pharmacists
0.75 Credit / Neurology, Psychiatry
View More
Treatment of Duchenne Muscular Dystrophy: Updates in Disease-Modifying Drugs
0.75 Credit / Neurology
View More
Therapeutic Strategies for Bipolar Disorder: Recognizing the Intricacies in Disease Management and Considerations for Pharmacists Across Practice Settings
2.0 Credits / Neurology, Psychiatry
View More
Strategies to Improve the Management of Migraine: Clinical Updates for Pharmacists and Patient-Case Review
1.0 Credit / Neurology
View More
Recognizing Rett Syndrome: Managed Care Insights on Disease Burden
1.5 Credits / Neurology, Rare Diseases
View More
Blarcamesine Deemed Safe, Effective in Phase 2 Extension Study of Parkinson Disease Dementia
Despite a pause in the trial due to the COVID-19 pandemic, patients who opted to continue treatment into the open-label extension demonstrated significant improvements in Parkinson disease dementia symptoms for up to 48 weeks.
Tiziana Announces Planned Phase 2 Study of Foralumab in Progressive Multiple Sclerosis
Foralumab, a fully human anti-CD3 monoclonal antibody, has had treatment effect demonstrated in patients with COVID-19 and with multiple sclerosis, as well as in healthy normal individuals.
Differences in Diagnosis and Prevention Between NMOSD and MS
March 29th 2023Michael Levy, MD, PhD, associate professor at Harvard Medical School, talked about the differences between multiple sclerosis and neuromyelitis optica spectrum disorder, the currently available treatments, and next steps in research.
Avadel Pharmaceuticals Urges FDA to Make Decision on Extended-Release Formulation of Sodium Oxybate
In a phase 3 study, extended-release sodium oxybate demonstrated statistically significant and clinically meaningful results in excessive daytime sleepiness, clinician’s assessment of patient’s functioning, and reduction in cataplexy attacks.
Milestone-Free Time Longer in IV Edaravone-Treated Patients With ALS, Administrative Claims Suggest
Time to milestones such as invasive and noninvasive ventilation, speech-generating devices, and hospice care took significantly longer while on intravenous edaravone.
New Analysis of Phase 3 Clarity AD Study Highlights Health and Economic Benefits From Lecanemab
At the willingness to pay threshold of $200,000 per QALY gained, the estimated annual value for lecanemab was $35,678 and $37,351 from the payer and societal perspectives, respectively.
BrainStorm Announces FDA AdComm Meeting for NurOwn Stromal Cell Therapy
NurOwn, an autologous mesenchymal stromal cell approach for ALS, failed to meet its primary end point in a pivotal phase 3 trial, but showed promising results on less severe forms of the disease in subsequent analyses.
NeurologyLive® Brain Games: March 26, 2023
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Muscular Dystrophy Association (MDA).
SYMBYX Neuro Light Therapy Wellness Helmet Positively Impacts Parkinson Disease Symptoms
Over a 12-week treatment period, patients with Parkinson disease on light therapy demonstrated statistically significant improvements of 58% and 40% in lower and upper limb coordination and movement.
Myasthenia Agent Zilucoplan Continues to Show Positive Efficacy in Long-Term Extension
In participants who received placebo during the parent studies, rapid improvements were observed as early as week 1 after switching to zilucoplan, and continued through week 12 of the extension period.